Famciclovir vs. aciclovir in immunocompetent patients with recurrent genital herpes infections: A parallel-groups, randomized, double-blind clinical trial

British Journal of Dermatology

Volumn 144, Issue 4, 2001, Pages 818-824

  Chosidow, O ^a   Drouault, Y ^b   Leconte Veyriac, F ^c   Aymard, M ^d   Ortonne, J P ^e   Pouget, F ^a   Revuz, J ^f   Decazes, J M ^g   Malkin, J E ^h  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b Groupe Hospitalier Cochin Saint Vincent de Paul ^*  (France)

^c Department of Biostatistics   (France)

^d Department of Virology ^*  (France)

^e CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^f HENRI MONDOR HOSPITAL   (France)

^g SAINT LOUIS HOSPITAL   (France)

^h INSTITUT ALFRED FOURNIER   (France)

Author keywords

Aciclovi; Famciclovir; Recurrent genital herpes

Indexed keywords

ACICLOVIR; FAMCICLOVIR;

ADULT; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GENITAL HERPES; HEALING; HERPES SIMPLEX VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

2-AMINOPURINE; ACYCLOVIR; ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; DOUBLE-BLIND METHOD; FEMALE; HERPES GENITALIS; HUMANS; IMMUNOCOMPETENCE; MALE; MIDDLE AGED; PRODRUGS; RECURRENCE; TREATMENT OUTCOME;

EID: 0035034951     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2133.2001.04139.x     Document Type: Article

References (19)

1. Genital herpes - How much of a public-health problem?
2. Frequent recovery of HIV-1 from genital herpes simplex virus lesions in HIV-1-infected men
3. Genital herpes simplex virus infections: Clinical manifestations, course and complications
4. Treatment of recurrent genital herpes simplex infections with oral acyclovir. A controlled trial
5. New antiherpesvirus agents.Their targets and therapeutic potential
6. Advances in antiviral therapy in dermatology
7. Patient-initiated, twice daily oral famciclovir for early recurrent genital herpes. A randomized, double-blind multicenter trial
8. Antiviral drugs
9. Valaciclovir versus aciclovir in patients initiated treatment of recurrent genital herpes: A randomised, double blind clinical trial
10. A randomized, placebo-controlled comparison of oral valacyclovir and acyclovir in immunocompetent patients with recurrent genital herpes infections
11. Sample preparation from blood, cells and other fluids
12. Diagnosis of herpes simplex encephalitis: Application of polymerase chain reaction to cerebrospinal fluid from brain-biopsied patients and correlation with disease
13. Comparison of two hybridization assays for the rapid detection of PCR amplified HSV genome sequences from cerebrospinal fluid
14. Trials to assess equivalence: The importance of rigorous methods
15. Claims of equivalence in medical research: Are they supported by the evidence?
16. Oral acyclovir for episodic treatment of recurrent genital herpes: Efficacy and safety
17. Genital herpes simplex virus (HSV) infection
18. Efficacy of oral acyclovir in the treatment of initial and recurrent genital herpes
19. Comparison of effects of famciclovir and valaciclovir on pathogenesis of herpes simplex virus type 2 in a murine infection model